FDA Grants Emergency Use Authorization For Anthrax Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
The ability to opt-out of the inoculation under the Anthrax Vaccine Immunization Program is one condition of FDA’s clearance of Anthrax Vaccine Adsorbed for the prevention of inhalation anthrax. The authorization is the first use of the Emergency Use Authorization under BioShield Act of 2004.
You may also be interested in...
COVID-19 Vaccines: FDA’s Broad Authority To Craft Narrow EUAs May Push Agency Out Of Its Comfort Zone
US FDA may not be comfortable using some of the powers the emergency use authorization statute provides to limit a product’s use; regulatory distinctions for EUAs go beyond the lower ‘may be effective‘ standard needed for an authorization versus an approval. EUAs come with a lot of other tools to micromanage use that aren’t available for most approvals.
Emergency Use Of Unapproved Drugs Outlined In FDA Draft Guidance
FDA action on requests for consideration will likely take place within hours or days in an emergency situation, according to the draft document. The agency also encourages submission of candidate products prior to an emergency “at the earliest possible time.”
Emergency Use Of Unapproved Drugs Outlined In FDA Draft Guidance
FDA action on requests for consideration will likely take place within hours or days in an emergency situation, according to the draft document. The agency also encourages submission of candidate products prior to an emergency “at the earliest possible time.”